Drug Name:
LYRICA CR CV

Generic Name and Formulations:
Pregabalin 82.5mg, 165mg, 330mg; ext-rel tabs.
Company:
Pfizer Inc.
Therapeutic Use:
Indications for LYRICA CR:
Neuropathic pain associated with diabetic peripheral neuropathy (DPN). Postherpetic neuralgia (PHN).
Adult:
Swallow whole. Take once daily after evening meal. DPN: initially 165mg daily, may increase to max 330mg/day within 1 week. PHN: initially 165mg daily, may increase to 330mg daily within 1 week; max 660mg/day if insufficient relief after 2–4wks. Conversion from Lyrica capsules, oral soln: see full labeling. For all: renal impairment (CrCl 30–60mL/min): reduce dose (see full labeling); (CrCl <30mL/min or hemodialysis): dose with Lyrica.
Children:
Not established.
Warnings/Precautions:
Avoid abrupt cessation (taper over ≥1 week). Discontinue if angioedema, hypersensitivity reactions, myopathy or markedly elevated creatine kinase levels occur. CHF. Ocular conditions. Diabetes (monitor skin integrity). Suicidal tendencies (monitor). Pregnancy. Nursing mothers: not recommended.
Interactions:
Potentiates CNS depression with alcohol, other CNS depressants. Additive edema, weight gain with thiazolidinediones. Increased risk of angioedema with concomitant ACEIs.
See Also:
Pharmacological Class:
Alpha-2 delta ligand.
Adverse Reactions:
Dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, thinking abnormal (primarily difficulty with concentration/attention), infection, asthenia, paresthesias, headache, fatigue; elevated creatine kinase, decreased platelets, arrhythmias (PR prolongation), male-mediated teratogenicity; may be tumorigenic.
Note:
Register patients in North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling (888) 233-2334.
How Supplied:
Caps—90; CR tabs—30; Soln—16oz
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Rectal Cancer: Adjuvant Chemotherapy May Improve OS After pCR
- Breast Cancer: Determining the Best Diet for Disease Prevention
- Hormone Therapy for Breast Cancer May Cause Diabetes
- Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers
- Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma